SCHEMBL25301282

SCHEMBL25301282

CCCOC(=O)n1cc(NC(=O)[C@H](O)CNC(=O)c2cccc(-c3cnn(C)c3)c2)nc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSV O60911 1/20 0.39
▸ CTSL P07711 1/20 0.39
▸ CTSB P07858 1/20 0.39
▸ CTSS P25774 1/20 0.39
▸ KIFC1 Q9BW19 1/20 0.39
▸ CSF1R P07333 1/20 0.39
▸ KIT P10721 1/20 0.39
▸ DYRK1A Q13627 10/20 0.38
▸ GSK3B P49841 9/20 0.38
▸ WNT1 P04628 8/20 0.38
▸ FGFR1 P11362 1/20 0.37
▸ FGFR3 P22607 1/20 0.37
▸ CREBBP Q92793 1/20 0.36
▸ ITGAV P06756 1/20 0.36
▸ ITGB6 P18564 1/20 0.36
▸ FYN P06241 1/20 0.36
▸ IRAK1 P51617 2/20 0.36
▸ IRAK4 Q9NWZ3 2/20 0.36
▸ CLK2 P49760 1/20 0.36
▸ CLK3 P49761 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25290177 1.00 CTSV (0.39) CTSVCTSLCTSBCTSSKIFC1
SCHEMBL25248340 1.00 CTSV (0.39) CTSVCTSLCTSBCTSSKIFC1
SCHEMBL25295933 0.95 CTSV (0.41) CTSVCTSLCTSBCTSSCSF1R
SCHEMBL25295934 0.95 CTSV (0.41) CTSVCTSLCTSBCTSSCSF1R
SCHEMBL25291840 0.89 CSF1R (0.41) CTSVCTSLCTSBCTSSCSF1R
SCHEMBL25254542 0.89 CSF1R (0.41) CTSVCTSLCTSBCTSSCSF1R
SCHEMBL25291841 0.89 CSF1R (0.41) CTSVCTSLCTSBCTSSCSF1R
SCHEMBL25814217 0.86 KIFC1 (0.52) KIFC1CSF1RKITDYRK1AGSK3B
SCHEMBL25297055 0.82 CTSV (0.39) CTSVCTSLCTSBCTSSCSF1R
SCHEMBL25297054 0.82 CTSV (0.39) CTSVCTSLCTSBCTSSCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2025-03-13 — — US disclosed
EP-4463444-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS Merck Patent GmbH (DE) 2024-11-20 — — EP disclosed
WO-2023131690-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2023-07-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS VHL, CDKN1A, CCNI CTSV 3246/4885CTSL 3949/4885CTSB 2443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback